Moderna三季度扭亏为盈,营收增长29%

Moderna Returns to Profit as Revenue Rises 29 Percent
Moderna三季度扭亏为盈,营收增长29%

Moderna reported third-quarter revenue of about 1.3 billion dollars on November 7, up 29 percent from a year earlier, and swung back to a profit of 0.38 dollars per share, well above analyst expectations for a loss of 1.28 dollars per share. US revenue totaled 780 million dollars and international revenue 533 million dollars, helped by deliveries under longer-term government COVID-19 vaccine contracts. The company has been cutting costs while developing products beyond its original vaccine business, and it highlighted positive late-stage clinical data for its investigational cancer therapy intismeran and regulatory progress on its influenza vaccine portfolio. Analysts cautioned that vaccine demand remains seasonal and that a single profitable quarter does not establish a steady earnings base.

Moderna 11月7日公布三季度财报,营收约13亿美元,同比增长29%;每股收益0.38美元,实现扭亏为盈,远好于分析师预期的每股亏损1.28美元。美国收入7.8亿美元,国际收入5.33亿美元,主要受长期政府新冠疫苗供应合同的交付推动。公司一直在削减成本,并在原有疫苗业务之外拓展产品,重点提到其研究性癌症疗法intismeran的三期临床数据积极,以及流感疫苗组合的监管进展。分析师提示,疫苗需求仍有季节性,单季盈利不足以建立稳定的盈利基础。

COVID-19 vaccine vials
新冠疫苗药瓶(示意图)

发表回复

您的邮箱地址不会被公开。 必填项已用 * 标注